These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17947507)

  • 1. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
    Shi J; Tricot GJ; Garg TK; Malaviarachchi PA; Szmania SM; Kellum RE; Storrie B; Mulder A; Shaughnessy JD; Barlogie B; van Rhee F
    Blood; 2008 Feb; 111(3):1309-17. PubMed ID: 17947507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I.
    Wu X; Shao Y; Tao Y; Ai G; Wei R; Meng X; Hou J; Han Y; Zhan F; Zheng J; Shi J
    Biochem Biophys Res Commun; 2011 Nov; 415(1):187-92. PubMed ID: 22033416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
    Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.
    Yang G; Gao M; Zhang Y; Kong Y; Gao L; Tao Y; Han Y; Wu H; Meng X; Xu H; Zhan F; Wu X; Shi J
    Oncotarget; 2015 Sep; 6(29):26982-94. PubMed ID: 26323098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
    Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
    Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
    Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
    Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.
    Hu W; Zheng RR; Cui HX; Yue D; Wang Y; Jiang YH
    Asian J Androl; 2012 Sep; 14(5):695-702. PubMed ID: 22902909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.
    Gao M; Gao L; Yang G; Tao Y; Hou J; Xu H; Hu X; Han Y; Zhang Q; Zhan F; Wu X; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2014 Jul; 46(7):597-604. PubMed ID: 24850305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
    David E; Sun SY; Waller EK; Chen J; Khuri FR; Lonial S
    Blood; 2005 Dec; 106(13):4322-9. PubMed ID: 16118318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.
    Shen L; Au WY; Wong KY; Shimizu N; Tsuchiyama J; Kwong YL; Liang RH; Srivastava G
    Mol Cancer Ther; 2008 Dec; 7(12):3807-15. PubMed ID: 19074855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
    Hallett WH; Ames E; Motarjemi M; Barao I; Shanker A; Tamang DL; Sayers TJ; Hudig D; Murphy WJ
    J Immunol; 2008 Jan; 180(1):163-70. PubMed ID: 18097016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
    Carbone E; Neri P; Mesuraca M; Fulciniti MT; Otsuki T; Pende D; Groh V; Spies T; Pollio G; Cosman D; Catalano L; Tassone P; Rotoli B; Venuta S
    Blood; 2005 Jan; 105(1):251-8. PubMed ID: 15328155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
    Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
    J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.
    Jinushi M; Vanneman M; Munshi NC; Tai YT; Prabhala RH; Ritz J; Neuberg D; Anderson KC; Carrasco DR; Dranoff G
    Proc Natl Acad Sci U S A; 2008 Jan; 105(4):1285-90. PubMed ID: 18202175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
    Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
    Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
    Armeanu S; Krusch M; Baltz KM; Weiss TS; Smirnow I; Steinle A; Lauer UM; Bitzer M; Salih HR
    Clin Cancer Res; 2008 Jun; 14(11):3520-8. PubMed ID: 18519785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effect of bortezomib on HLA class I and class II antibody.
    Philogene MC; Sikorski P; Montgomery RA; Leffell MS; Zachary AA
    Transplantation; 2014 Sep; 98(6):660-5. PubMed ID: 24798311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
    Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
    Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
    Lundqvist A; Yokoyama H; Smith A; Berg M; Childs R
    Blood; 2009 Jun; 113(24):6120-7. PubMed ID: 19202127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
    Yong AS; Keyvanfar K; Hensel N; Eniafe R; Savani BN; Berg M; Lundqvist A; Adams S; Sloand EM; Goldman JM; Childs R; Barrett AJ
    Blood; 2009 Jan; 113(4):875-82. PubMed ID: 18922853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.